Organometallic Ligands

Ondansetron is a serotonin 5-HT3 receptor antagonist that has been shown to inhibit the effects of serotonin in the gastrointestinal tract, thereby preventing nausea and vomiting that is caused by cancer chemotherapy. Chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, initiating a vomiting reflex through stimulation of 5-HT3 receptors located on vagal afferents. Ondansetron blocks the initiation of this reflex. The drug binds to receptors on cells in the gastrointestinal tract that are normally activated by serotonin, thereby blocking its effect. Ondansetron hydrochloride is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

LY 334370 Hydrochloride is a selective 5-HT1F receptor agonist, which is a chemical compound derived from advanced synthetic processes. As an agonist, it specifically targets the 5-HT1F receptor, a subtype of serotonin receptor that is implicated in neurovascular modulation. The selective activation of this receptor is thought to inhibit pro-inflammatory neuropeptide release and modulate pain pathways within the central nervous system. LY 334370 Hydrochloride is primarily utilized in the research and study of migraine mechanisms. Its ability to selectively bind to the 5-HT1F receptor makes it a valuable tool for investigating the therapeutic potential of receptor-specific agonists in the prophylaxis and management of migraines. Researchers leverage this compound to better understand the underlying pathophysiology of migraines and the role of serotonin receptors in their management, potentially guiding the development of targeted therapies with improved efficacy and reduced side effects compared to non-specific treatments.

Tat-cyclo-cllfvy is a cell-penetrating peptide, which is a synthetic compound designed for therapeutic applications. It is derived from natural peptide sequences, engineered to facilitate efficient cellular uptake without significant toxicity or disruption of cellular membranes. The mode of action involves the facilitated transport of the peptide across the lipid bilayer of cells, leveraging its amphipathic structure to interact with cellular membranes and enable intracellular delivery of attached therapeutic agents. The primary uses and applications of Tat-cyclo-cllfvy are in the fields of drug delivery and biochemical research. It serves as a vector for delivering a variety of molecular cargoes, including small molecules, proteins, and nucleic acids, into cells. This capability is particularly valuable for targeting intracellular pathways and investigating cellular responses, making it a crucial tool for the development of novel therapeutics and the study of complex biological systems. The ability to modify and attach different types of therapeutic agents makes Tat-cyclo-cllfvy a versatile and powerful agent in advanced biomedical research and therapy development.

GSK2983559 is an investigative compound, which is a small-molecule therapeutic derived from pharmaceutical research. This compound is synthesized through advanced medicinal chemistry techniques employed by GlaxoSmithKline (GSK) to target specific biological mechanisms. The active metabolite of GSK2983559 exerts its effects primarily by modulating molecular pathways involved in inflammation, specifically inhibiting certain immune cell signaling cascades. This selective mechanism of action is designed to reduce the inflammatory response that is characteristic of autoimmune and other inflammatory conditions. By targeting these pathways, GSK2983559 holds potential for therapeutic intervention in disorders characterized by excessive inflammation, such as rheumatoid arthritis and inflammatory bowel disease. Researchers are actively exploring its efficacy and safety profile in preclinical and clinical studies. Scientifically, it contributes valuable insights into the modulation of immune responses and offers a promising approach to treating inflammatory diseases by potentially minimizing the adverse effects associated with broader immunosuppressive therapies.

AZD3229 Tosylate is a small molecule tyrosine kinase inhibitor, which is derived through advanced chemical synthesis methodologies. The compound acts by selectively targeting and inhibiting specific receptor tyrosine kinases, which play a crucial role in the signaling pathways that regulate cellular processes such as proliferation, differentiation, and survival. The compound is primarily investigated for its potential application in oncology, where aberrant kinase activity often underpins tumor growth and metastasis. By obstructing these signaling pathways, AZD3229 Tosylate aims to impede tumor progression and enhance the efficacy of other therapeutic strategies. Its potency and selectivity make it a promising candidate for further research and clinical trials to assess its efficacy and safety in cancer treatment regimens. This molecule's development underscores the ongoing advancements in targeted cancer therapies, which seek to exploit the specific molecular vulnerabilities of cancer cells while minimizing damage to normal tissues.

CCT137690 is a chemical inhibitor, which is a synthetic compound developed through medicinal chemistry. Its primary mode of action is the selective inhibition of Cyclin-dependent kinases 8 and 19 (CDK8 and CDK19), which are part of the Mediator complex crucial for regulating transcription and gene expression. By interfering with these kinases, CCT137690 impacts the transcriptional regulation pathways that are critical for cancer cell proliferation and survival. In the context of scientific research, CCT137690 is utilized extensively for interrogating the role of CDK8 and CDK19 within cancer biology. Its application can lead to insights into how these kinases contribute to oncogenesis, offering a potential pathway for therapeutic intervention in cancers where these pathways are dysregulated. This compound serves as a tool to dissect the mechanistic role of transcriptional modulation in various cellular processes, thereby aiding in the development of targeted cancer therapies. Researchers leverage CCT137690 to explore its potential in modulating signal transduction pathways and to derive significant conclusions about its efficacy and mechanism of action in preclinical models.

1,2-Dipalmitoyl-d62-sn-glycero-3-phosphocholine-N,N,N-trimethyl-d9 is a deuterated phospholipid, which is an important tool in biophysical research. This molecule is sourced from the synthetic modification of natural phosphatidylcholine, incorporating deuterium atoms to enhance its utility in specialized studies. The deuterium labeling replaces hydrogen atoms, which significantly reduces background noise and enhances signal clarity in spectroscopic techniques like NMR and neutron scattering. The primary mode of action involves integrating into lipid bilayers where it mimics the behavior of natural phospholipids, while the deuterium labeling allows for detailed observation of molecular dynamics and structure. This property facilitates advanced investigations of membrane organization, lipid-protein interactions, and the biophysical properties of lipid assemblies. Applications of 1,2-Dipalmitoyl-d62-sn-glycero-3-phosphocholine-N,N,N-trimethyl-d9 are particularly significant in the study of biological membranes, providing insight into fundamental cellular processes. Its use is critical in elucidating structures within lipid domains and understanding mechanistic pathways that govern membrane-associated activities.

Cetilistat is a drug that is used to treat obesity. This drug inhibits the enzyme pancreatic lipase and so it prevents triglycerides from being hydrolyzed into absorbable free fatty acids. Cetilistat is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Long-acting muscarinic antagonist

During extraction of lecithin from egg yolk, peptide by-products can be isolated and purified by gel filtration. Within the by-products this has led to the discovery of biologically active value-added products. The egg yolk gel filtration (EFGF) fractions were analysed for their antioxidant and angiotensin converting enzyme (ACE) inhibitory activities. EYGF-56 predominantly contained 3 peptides - SDNRNQGY, KGLWE, and IQVPL. KGLWE in EYGF-56 was found to have very strong antioxidant activity. KGLWE showed minimal angiotensin converting enzyme (ACE) inhibitory activity.

2-Amino-3-phosphonopropanoic acid is a chemical compound classified as a phosphonic acid derivative, which is obtained through synthetic processes in a laboratory setting. It acts as a selective antagonist of metabotropic glutamate receptors (mGluRs), specifically inhibiting the function of these receptors by blocking the normal action of the neurotransmitter glutamate, which is a critical excitatory neurotransmitter in the central nervous system. This blockade affects synaptic transmission and modulates neurological signals. In neuroscience research, 2-Amino-3-phosphonopropanoic acid is primarily utilized to study the role of glutamate receptors in neural communication, plasticity, and neurodegenerative diseases. By elucidating the pathways and mechanisms regulated by these receptors, researchers can better understand various cognitive processes and pathologies associated with glutamate dysregulation, such as epilepsy, ischemia, and neurotoxicity. This compound thus provides a valuable tool for probing the intricate signaling networks within the brain and exploring potential therapeutic targets.

Inhibits osteoclast resorption; anti-hypercalcemic

Bruton's tyrosine kinase antagonist; reduces Fcγ receptor signaling

UFP-101 is a synthetic antimicrobial compound, which is engineered from advanced chemical synthesis methodologies with unique molecular modifications. The compound acts by disrupting microbial cell membranes, resulting in cell lysis and death. This mode of action is particularly effective against a broad spectrum of bacterial strains, including multi-drug-resistant varieties. The applications of UFP-101 are extensive within both clinical and industrial settings. In the medical field, it is being explored as a potential agent for the treatment of resistant infections, with ongoing research focusing on its efficacy in wound care and surgical site prophylaxis. Additionally, due to its robust action against a wide range of pathogens, UFP-101 is also being tested for use in decontamination processes in laboratories and healthcare environments, contributing to infection control efforts. Researchers are particularly interested in its integration into coatings and materials that require strong antimicrobial properties, potentially pioneering a new class of infection-preventive applications.

Muscle relaxant; anti-inflammatory

Prostanoid receptor agonist

Pf-06412154 hydrochloride is an investigational anti-inflammatory agent, which is synthesized chemically. It functions as a selective inhibitor of Janus kinases (JAK), crucial enzymes involved in the signaling pathways of various cytokines and growth factors. By inhibiting JAK activity, Pf-06412154 disrupts the JAK-STAT pathway, which is implicated in the pathogenesis of several inflammatory and autoimmune disorders. This mode of action is intended to reduce the expression of inflammatory cytokines, offering potential therapeutic benefits. Pf-06412154 hydrochloride is being explored for its application in treating conditions such as rheumatoid arthritis and other autoimmune diseases, where dysregulated JAK-STAT signaling plays a significant role in disease progression. The compound's specificity for JAK enzymes aims to minimize off-target effects and improve therapeutic outcomes compared to broader immunosuppressive therapies. As an experimental drug, it is currently undergoing preclinical or clinical evaluation to assess its efficacy, safety, and pharmacokinetic properties in relevant patient populations.

GNA002 is a selective inhibitor of viral RNA-dependent RNA polymerases, which is a synthetic antiviral compound. Its source is a series of rationally designed molecules targeting viral replication machinery, specifically tailored to hinder the replication of RNA viruses by obstructing the activity of their RNA polymerases. The mode of action involves binding to a site on the viral RNA-dependent RNA polymerase that is distinct from the nucleotide-binding site, which results in a disruption of the elongation of the viral RNA strand. The uses and applications of GNA002 are primarily centered on its antiviral properties, making it a potential therapeutic agent in the treatment of diseases caused by RNA viruses. This includes common pathogens such as influenza and more emerging viral threats like those caused by coronaviruses. Its precise mechanism of action offers a targeted approach, potentially leading to reduced viral loads in infected hosts and improved clinical outcomes. Furthermore, its specificity might mitigate the development of resistance, a common hurdle in antiviral treatment regimes. Ongoing research explores its efficacy across different viral strains and its potential role in antiviral drug combinations.

Valsartan is an angiotensin receptor blocker that is used to treat hypertension and in combination with other antihypertensive agents. This drug works by binding to the angiotensin receptor 1 (AT1) and preventing angiotensin II from binding and exerting its hypertensive effects. This leads to a reduction in blood pressure and reduced cardiac activity. Valsartan is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Lomustine is an alkylating agent that is used as chemotherapy for treating metastatic brain tumors and relapsed Hodgkin’s disease in combination with radiation treatments. This drug causes alkylation and cross-linking of DNA, thus inducing cytotoxicity. Furthermore, this drug inhibits DNA synthesis. Lomustine is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.